Intracellular targets, eye cancer therapy and light-activated skincare: Here's the latest on biotech IPOs
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here.
The busy IPO season shows no sign of slowing, with three more biotechs trick-or-treating for their own stock tickers and some sweet raises Thursday.
Entrada Therapeutics, Biofrontera Inc. and Aura Biosciences — all based in Massachusetts — hit Nasdaq just before the end of the week.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.